Floatz logo

Bvd-523

Uveal Melanoma

Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

64 Active assets in the Uveal Melanoma cohort.

Asset / SponsorPhaseRating
Ifa
Craig L Slingluff, Jr
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2/3BB
Sargramostim
Thomas Jefferson University
Phase 3BB
Gm-Csf
Ahmad Tarhini
Phase 2BB

View all 50 →

Same molecule, other indications

Bvd-523 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
40 / 100
View asset →
myelodysplastic syndromeDormant
C
Indicative ·
38 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →